Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 27939400

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet
Publication date
2017 Jan 7
First author
Balar AV

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2017 Jan 7;389(10064):6-7. doi: 10.1016/S0140-6736(16)32516-8.
    note
    Source null
    related pmid
    27939401
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2017 Mar;14(3):139. doi: 10.1038/nrclinonc.2016.222.
    note
    Source null
    related pmid
    28031559
    relationship
    Comment in
  3. citation
    Nat Rev Urol. 2017 Feb;14(2):67. doi: 10.1038/nrurol.2016.271.
    note
    Source null
    related pmid
    28031561
    relationship
    Comment in
  4. citation
    Lancet. 2017 Aug 26;390(10097):848. doi: 10.1016/S0140-6736(17)32213-4.
    note
    Source null
    related pmid
    28807535
    relationship
    Erratum in

Authors and identifiers

  1. name
    Balar AV
    type
    Author
  2. name
    Galsky MD
    type
    Author
  3. name
    Rosenberg JE
    type
    Author
  4. name
    Powles T
    type
    Author
  5. name
    Petrylak DP
    type
    Author
  6. name
    Bellmunt J
    type
    Author
  7. name
    Loriot Y
    type
    Author
  8. name
    Necchi A
    type
    Author
  9. name
    Hoffman-Censits J
    type
    Author
  10. name
    Perez-Gracia JL
    type
    Author
  11. name
    Dawson NA
    type
    Author
  12. name
    van der Heijden MS
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Balar AV
    type
    Author
  2. name
    Galsky MD
    type
    Author
  3. name
    Rosenberg JE
    type
    Author
  4. name
    Powles T
    type
    Author
  5. name
    Petrylak DP
    type
    Author
  6. name
    Bellmunt J
    type
    Author
  7. name
    Loriot Y
    type
    Author
  8. name
    Necchi A
    type
    Author
  9. name
    Hoffman-Censits J
    type
    Author
  10. name
    Perez-Gracia JL
    type
    Author
  11. name
    Dawson NA
    type
    Author
  12. name
    van der Heijden MS
    type
    Author
bibliography ids
  1. nci-bib-91eb2d230c3609c0afda5feb
book metadata
content sha256
d4c7d8bc20fedc5cf857a15b24f8acb2fa52f9b7affdff8ee92327211e5b8d8e
document type
citation
dois
  1. 10.1016/S0140-6736(16)32455-2
electronic publication date
display
2016 Dec 8
precision
day
year
2016
evidence scope
bibliographic_metadata_only
id
pubmed:27939400
immutable id
pubmed:27939400@d4c7d8bc20fedc5cf857a15b24f8acb2fa52f9b7affdff8ee92327211e5b8d8e
journal
abbreviation
Lancet
issn electronic
1474-547X
issn print
0140-6736
issue
10064
name
Lancet (London, England)
nlm unique id
2985213R
pages
67-76
volume
389
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2017 Jan 7;389(10064):6-7. doi: 10.1016/S0140-6736(16)32516-8.
    note
    Source null
    related pmid
    27939401
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2017 Mar;14(3):139. doi: 10.1038/nrclinonc.2016.222.
    note
    Source null
    related pmid
    28031559
    relationship
    Comment in
  3. citation
    Nat Rev Urol. 2017 Feb;14(2):67. doi: 10.1038/nrurol.2016.271.
    note
    Source null
    related pmid
    28031561
    relationship
    Comment in
  4. citation
    Lancet. 2017 Aug 26;390(10097):848. doi: 10.1016/S0140-6736(17)32213-4.
    note
    Source null
    related pmid
    28807535
    relationship
    Erratum in
outcomes validated
false
pmid
27939400
provenance
batch id
7a1288ac8bb5f9826304
provider
NCBI PubMed ESummary
record sha256
efaacac5660e9cd5d485a106c2164dc2a4676d4ca92040f829cdee9a09c096fc
response sha256
0e879bec8c19d1cfda5629dca8745b04155d18cf54361825d4c070aebad2984d
retrieved at
2026-09-09T23:47:23.138359+00:00
publication date
display
2017 Jan 7
precision
day
year
2017
publication types
  1. Clinical Trial, Phase II
  2. Journal Article
  3. Multicenter Study
  4. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/27939400/
title
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.

Preserved source evidence · Not medical advice